{"entity":{"id":"azd5863","kind":"drug","name":"AZD5863","aka":[],"tldr":"AZD5863 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer, aimed at Claudin 18.2 and CD3.","summary":"AZD5863 is a bispecific antibody developed by AstraZeneca. Its targets are Claudin 18.2 and CD3 (the sponsor names CLDN18.2 x CD3). The sponsor states: T cell-engaging bispecific antibody that binds Claudin 18.2 on tumour cells and CD3 on T cells, bridging them to drive immune-mediated tumour cell killing. ClinicalTrials.gov describes the intervention as: T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumour cells and CD3 on T cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer. The largest, NCT06005493, plans to enrol 280 participants with primary completion expected 2027-07-16. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD5863","url":"https://clinicaltrials.gov/search?intr=AZD5863"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","pancreatic","esophageal"],"sections":[],"technologies":[],"targets":["cldn18-2","cd3"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06005493"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"T cell-engaging bispecific antibody that binds Claudin 18.2 on tumour cells and CD3 on T cells, bridging them to drive immune-mediated tumour cell killing.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd5863/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06005493","kind":"trial","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06005493/"}]}}